

UNITED STATES CONTINUING UTILITY PATENT APPLICATION

under 37 C.F.R. § 1.53(b)

Atty. Docket No. 1765.80234

Page 1

Assistant Commissioner of Patents
Box Patent Applications
Washington, D.C. 20231

Enclosed herewith is a continuing patent application and the following papers:

First Named Inventor (or application identifier): Michael L. Vazquez

Title of Invention: α and β -Amino Acid Hydroxyethylamino Sulfonamides Useful As Retroviral Protease Inhibitors

- ☒ Continuation
- ☐ Divisional
- ☐ Continuation-in-Part

of prior application No. 08/294,468, filed August 23, 1994

1. ☒ Specification 274 pages (including specification, claims, abstract) / 20 claims (2 independent)
2. ☒ Declaration/Power of Attorney:
 - ☒ Copy from Prior Application (for continuation or divisional application)
 - ☐ Newly Executed Declaration (for CIP application)
 - ☐ Deferred under 37 C.F.R. § 1.53(f)
 - ☐ Deletion of Inventor(s) - Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b)
 - ☒ Incorporation by Reference - The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein
3. ☒ This Application has no drawings.
4. ☒ Preliminary Amendment
5. ☐ Information Disclosure Statement
 - ☐ Form 1449
 - ☐ A copy of each cited prior art reference
6. ☒ Assignment
 - ☐ Assignment with Cover Sheet attached
 - ☒ Assignment filed in prior application. Application assigned to: G.D. Searle & Co.

JC518 U.S. PTO
09/288080
04/08/99

A

UNITED STATES CONTINUING UTILITY PATENT APPLICATION
under 37 C.F.R. § 1.53(b)

Page 2

Atty. Docket No. 1765.80234

7. ☐ Priority is hereby claimed under 35 U.S.C. § 119 based upon the following application(s):

Country	Application Number	Date of Filing (day, month, year)

8. ☐ Priority document(s)

9. ☐ Small Entity Statement

- ☐ Small Entity Statement was filed in prior application, Small Entity Status is still proper and desired
☐ is attached
☐ is no longer claimed

10. ☐ Microfiche Computer Program (Appendix)

11. ☐ Nucleotide and/or Amino Acid Sequence Submission

- ☐ Computer Readable Copy
☐ Paper Copy (identical to computer copy)
☐ Statement verifying identity of above copies

12. Calculation of Fees (upon entry of Preliminary Amendment):

FEES FOR	EXCESS CLAIMS	FEE	AMOUNT DUE
Basic Filing Fee (37 C.F.R. § 1.16(a))			\$760.00
Total Claims in Excess of 20 (37 C.F.R. § 1.16(c))	0	18.00	\$0.00
Independent Claims in Excess of 3 (37 C.F.R. § 1.16(b))	0	78.00	\$0.00
Multiple Dependent Claims (37 C.F.R. § 1.16(d))	0	260.00	\$0.00
Subtotal - Filing Fee Due			\$760.00
	MULTIPLY BY		
Reduction by 50%, if Small Entity (37 C.F.R. §§ 1.9, 1.27, 1.28)	0		\$0.00
TOTAL FILING FEE DUE			\$760.00
Assignment Recordation Fee (if applicable) (37 C.F.R. § 1.21(h))	0	40.00	\$0.00
GRAND TOTAL DUE			\$760.00

13. PAYMENT is:

- ☒ included in the amount of the GRAND TOTAL by our enclosed check. A general authorization under 37 C.F.R. § 1.25(b), second sentence, is hereby given to credit or debit our Deposit Account No. 19-0733 for the instant filing of this application under 37 C.F.R. §§ 1.16, 1.17 and 1.18
☐ not included, but deferred under 37 C.F.R. § 1.53(f).

A

under 37 C.F.R. § 1.53(b)

Atty. Docket No. 1765.80234

- 14. All correspondence for the attached application should be directed to:**

Facsimile: (202) 508-9299

15. Other: _____

Date: April 8, 1999

By:

Reg. No. 29,864

JMS/rkb

[illegible]

A